|Articles|April 14, 2020
Kayentis Forges Ahead on New eCOA Service Projects
Advertisement
Kayentis has announced it is forging ahead on five new eCOA service projects with Emerging BioPharma companies. The projects Kayentis is collaborating on involve phase II and III clinical studies in therapeutic areas addressing unmet needs in areas like oncology, immune disorders, and rare diseases. In response to COVID-19, Kayentis has implemented a dedicated contingency plan for sites and patients to keep trials running.
For more information, click
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Clinical Trials in 2026: Platformization, AI Fluency, and the Redrawing of the Value Chain
2
Moving Beyond Historical Site Data to Real-Time Patient Insight
3
ACT Brief: Community Sites Compete on Readiness, COA Licensing Bottlenecks Slow Start-Up, and AI’s Foundations in Pharmacovigilance
4
How Community Sites Can Stay Competitive Under Growing Efficiency Pressures
5